Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Treatment for atrial fibrillation was initiated, including rate control and anticoagulation with 5 mg of apixaban two times per day for primary stroke prophylaxis. Three days after initiation of ...

3,8 Patients with AF and at least one risk factor for stroke were randomised to receive either dose-adjusted warfarin (international normalised ratio (INR) 2–3) or apixaban 5 mg twice daily. A reduced ...

We decided to resolve the thrombus at our outpatient clinic. He was started on the novel oral anticoagulant, apixaban, 2.5 mg twice daily, which is a direct factor Xa (FXa) inhibitor. After 11 weeks ...

Patients will be randomized 1:1 to receiving apixaban 5 mg twice daily or warfarin with a target international normalized ratio of 2.0-3.0. The last randomized participant will be followed for at ...

The apixaban prescription was compared with the labeling; ordering a 2.5 mg regimen among patients who did not fulfill the dose adjustment criteria was defined as an off-label underdose, and ordering ...

The Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) randomized clinical trial compared apixaban 5 or 2.5 mg twice daily to aspirin 81 mg once daily for ...

13 This randomized, double-blind study evaluated apixaban, given in 5mg doses twice a day or in adjusted dose of 2.5 mg, twice a day, in patients with at least two of the three following factors: age ...

The efficacy and safety of apixaban for VTE prophylaxis in major orthopedic surgery have been evaluated in one Phase II trial and three Phase III trials. Traditional treatment of acute VTE entails ...